NEWS
[Retail Market] "Ganmao Ling Granules & Compound Ganmao Ling Granules" Product Market Analysis Report
The monthly sales trends of Ganmaoling Granules and Compound Ganmaoling Granules at the retail end tend to be consistent.
The monthly sales trends of Ganmaoling Granules and Compound Ganmaoling Granules at the retail end tend to be consistent, with Ganmaoling Granules having a stronger sales capability, approximately three times that of Compound Ganmaoling Granules; consumers have a stronger demand for them in winter.
The sales of both types of medicines show a fluctuating trend, with sales peaking in winter (especially from November to January of the following year), which may be related to the high incidence of colds in winter and increased public demand; the store-level order index for Ganmaoling Granules is higher than the baseline period (≥100), indicating a certain market share and a stable consumer base in the retail market.
The top 3 provinces/cities for high store-level sales of Ganmaoling Granules are southern cities—Fujian, Chongqing, and Guangdong—with Guangdong, Henan, and Guangxi showing faster growth; the top 3 provinces/cities for store-level sales of Compound Ganmaoling Granules are Chongqing, Zhejiang, and Sichuan, with Guizhou and Hunan showing high growth rates.
Consumer age profile: The two products tend to be consistent in consumer gender and age, with a male-to-female ratio close to 4:6, the main age group for purchasing medicine being 36-45 years old, and the per capita consumption power of older male groups being significantly stronger.
Xiao Chaihu Granules (traditional Chinese medicine, for relieving exterior syndrome, dispersing heat, soothing liver and stomach) and Amoxicillin Capsules (Western medicine, broad-spectrum penicillin antibiotic) are the high cross-purchase medicines when consumers buy Ganmaoling Granules and Compound Ganmaoling Granules respectively; among the Compound Ganmaoling Granules purchasing group, 2.6% also cross-purchase Ganmaoling Granules.
Hot news
Shengnuo Bio has signed a strategic agreement with a Brazilian "Belt and Road" institution to cooperate on the supply of peptide APIs, technology exchange, and market channel development, with a focus on promoting GLP-1 class APIs such as Semaglutide and Tirzepatide in the Brazilian market. This collaboration marks the extension of the company's overseas presence into the core South American market and provides a practical pathway for China-Brazil biomedical cooperation under the "Belt and Road" framework.
2025-12-08
The 93rd API China kicked off successfully in Chongqing on November 12, with Shengnuo Biopharm (Booth N5 Hall 5L25) getting off to a strong start on the first day. The exhibition floor was buzzing with professional exchanges, as the company's demonstration of its integrated, end-to-end capabilities in peptide APIs and CDMO services attracted numerous industry professionals for in-depth discussions and garnered widespread recognition. The exhibition is still ongoing, and we sincerely invite colleagues from across the industry to visit our booth to continue the dialogue and explore collaborative opportunities.
2025-11-12
Chengdu Shengnuo Biopharm sincerely invites you to attend the 93rd China International Pharmaceutical Raw Materials, Intermediates, Packaging, and Equipment Trade Fair (API China 2025). Join us from November 12–14, 2025, at Booth No. 5L25, Hall N5, Chongqing International Expo Center, as we explore cutting-edge technologies and collaboration opportunities in the peptide sector.
2025-11-11
October 30, 2025 – Chengdu Shengnuo Biopharm Co., Ltd. held the project commencement ceremony in Dayi Economic Development Zone, marking the official start of construction for the Semaglutide, Tirzepatide, and other peptide Active Pharmaceutical Ingredient (API) industrialization base project.
2025-10-31